DE60042620D1
(de)
*
|
1999-05-21 |
2009-09-03 |
Bristol Myers Squibb Co |
Pyrrolotriazine als Kinase Hemmer.
|
JP4623483B2
(ja)
*
|
1999-08-23 |
2011-02-02 |
塩野義製薬株式会社 |
sPLA2阻害作用を有するピロロトリアジン誘導体
|
KR20030029812A
(ko)
*
|
2000-08-09 |
2003-04-16 |
아스트라제네카 아베 |
화학적 화합물
|
US6756383B2
(en)
|
2000-09-01 |
2004-06-29 |
Chiron Corporation |
Heterocyclic derivatives of quinolinone benimidazoles
|
US20030028018A1
(en)
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
AP1666A
(en)
|
2000-09-11 |
2006-09-29 |
Chiron Corp |
Quinolinone derivatives as tyrosine kinase inhibitors.
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
CN1622946A
(zh)
*
|
2000-11-17 |
2005-06-01 |
布里斯托尔-迈尔斯斯奎布公司 |
治疗与p38激酶有关的症状的方法以及用作激酶抑制剂的吡咯并三嗪化合物
|
US6699890B2
(en)
|
2000-12-22 |
2004-03-02 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
PL373301A1
(en)
*
|
2001-01-22 |
2005-08-22 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
US7153871B2
(en)
|
2001-01-22 |
2006-12-26 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
|
US7205320B2
(en)
|
2001-01-22 |
2007-04-17 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
TW200300350A
(en)
*
|
2001-11-14 |
2003-06-01 |
Bristol Myers Squibb Co |
C-5 modified indazolylpyrrolotriazines
|
SE0200979D0
(sv)
|
2002-03-28 |
2002-03-28 |
Astrazeneca Ab |
New compounds
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
SE0302546D0
(sv)
|
2003-09-24 |
2003-09-24 |
Astrazeneca Ab |
New compounds
|
FR2838123B1
(fr)
*
|
2002-04-04 |
2005-06-10 |
Sanofi Synthelabo |
Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
|
WO2003090912A1
(en)
*
|
2002-04-23 |
2003-11-06 |
Bristol-Myers Squibb Company |
Pyrrolo-triazine aniline compounds useful as kinase inhibitors
|
US7388009B2
(en)
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
PL373371A1
(en)
|
2002-04-23 |
2005-08-22 |
Bristol-Myers Squibb Company |
Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
|
TW200400034A
(en)
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
EP1539931A4
(de)
*
|
2002-06-27 |
2006-08-23 |
Univ Queensland |
Differenzierungsmodulierende agentien und verwendungen dafür
|
NZ537724A
(en)
|
2002-07-19 |
2006-10-27 |
Memory Pharm Corp |
Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
|
US6933386B2
(en)
|
2002-07-19 |
2005-08-23 |
Bristol Myers Squibb Company |
Process for preparing certain pyrrolotriazine compounds
|
NZ537725A
(en)
|
2002-07-19 |
2006-08-31 |
Memory Pharm Corp |
6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
|
KR100869417B1
(ko)
*
|
2002-07-19 |
2008-11-21 |
브리스톨-마이어스 스큅 컴퍼니 |
신규한 키나제 억제제
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
EP1388541A1
(de)
*
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazine als Kinasehemmer
|
CA2496164C
(en)
|
2002-08-23 |
2010-11-09 |
Chiron Corporation |
Benzimidazole quinolinones and uses thereof
|
MXPA05005345A
(es)
|
2002-11-19 |
2005-08-26 |
Memory Pharm Corp |
Inhibidores de fosfodiesterasa 4.
|
TW200420565A
(en)
*
|
2002-12-13 |
2004-10-16 |
Bristol Myers Squibb Co |
C-6 modified indazolylpyrrolotriazines
|
CA2515218A1
(en)
|
2003-02-05 |
2004-08-26 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine kinase inhibitors
|
US7102001B2
(en)
|
2003-12-12 |
2006-09-05 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine
|
MY145634A
(en)
*
|
2003-12-29 |
2012-03-15 |
Bristol Myers Squibb Co |
Pyrrolotriazine compounds as kinase inhibitors
|
US7064203B2
(en)
*
|
2003-12-29 |
2006-06-20 |
Bristol Myers Squibb Company |
Di-substituted pyrrolotriazine compounds
|
ATE433979T1
(de)
|
2004-04-02 |
2009-07-15 |
Osi Pharm Inc |
Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
UY28931A1
(es)
*
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
US7102002B2
(en)
|
2004-06-16 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
TW200600513A
(en)
|
2004-06-30 |
2006-01-01 |
Bristol Myers Squibb Co |
A method for preparing pyrrolotriazine compounds
|
US7102003B2
(en)
*
|
2004-07-01 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds
|
MY139689A
(en)
*
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
WO2006044687A2
(en)
*
|
2004-10-15 |
2006-04-27 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
US7151176B2
(en)
*
|
2004-10-21 |
2006-12-19 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds
|
US7759337B2
(en)
|
2005-03-03 |
2010-07-20 |
Amgen Inc. |
Phthalazine compounds and methods of use
|
US7534882B2
(en)
|
2005-04-06 |
2009-05-19 |
Bristol-Myers Squibb Company |
Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
|
AR053710A1
(es)
|
2005-04-11 |
2007-05-16 |
Xenon Pharmaceuticals Inc |
Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
|
AR056968A1
(es)
|
2005-04-11 |
2007-11-07 |
Xenon Pharmaceuticals Inc |
Compuestos espiro-oxindol y composiciones farmacéuticas
|
KR100695700B1
(ko)
*
|
2005-04-20 |
2007-03-15 |
김세중 |
조립식 경량벽체 패널과 그 조립구조
|
KR100672087B1
(ko)
*
|
2005-04-25 |
2007-01-19 |
재단법인 포항산업과학연구원 |
폐단형 스터드부재 및 이를 이용한 단열 벽체 시스템
|
WO2006125130A1
(en)
|
2005-05-17 |
2006-11-23 |
Novartis Ag |
Methods for synthesizing heterocyclic compounds
|
US7576082B2
(en)
*
|
2005-06-24 |
2009-08-18 |
Hoffman-La Roche Inc. |
Oxindole derivatives
|
US7405213B2
(en)
|
2005-07-01 |
2008-07-29 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
|
US7402582B2
(en)
*
|
2005-07-01 |
2008-07-22 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
|
EP2182078B1
(de)
|
2005-09-01 |
2012-02-01 |
Bristol-Myers Squibb Company |
Biomarker und Verfahren zur Bestimmung der Empfindlichkeit gegen VEGFR2 modulator.
|
US7880004B2
(en)
|
2005-09-15 |
2011-02-01 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
US7547782B2
(en)
|
2005-09-30 |
2009-06-16 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
ES2401099T3
(es)
|
2005-11-02 |
2013-04-16 |
Bayer Intellectual Property Gmbh |
Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
|
US7514435B2
(en)
*
|
2005-11-18 |
2009-04-07 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7348325B2
(en)
|
2005-11-30 |
2008-03-25 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
WO2007064931A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Bayer Healthcare Llc |
Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
US8063208B2
(en)
|
2006-02-16 |
2011-11-22 |
Bristol-Myers Squibb Company |
Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
|
ES2427924T3
(es)
|
2006-06-30 |
2013-11-04 |
Merck Sharp & Dohme Corp. |
Biomarcador IGFBP2
|
JP5185930B2
(ja)
|
2006-07-07 |
2013-04-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
ピロロトリアジンキナーゼ阻害剤
|
EP2049542B1
(de)
|
2006-08-09 |
2012-09-19 |
Bristol-Myers Squibb Company |
Pyrrolotriazin-kinasehemmer
|
US7531539B2
(en)
|
2006-08-09 |
2009-05-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
EP2073806B1
(de)
|
2006-10-12 |
2012-02-15 |
Xenon Pharmaceuticals Inc. |
Verwendung von spiro-oxindol-verbindungen als therapeutika
|
US7982033B2
(en)
|
2006-11-03 |
2011-07-19 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US8268998B2
(en)
|
2006-11-03 |
2012-09-18 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
WO2008086128A2
(en)
*
|
2007-01-05 |
2008-07-17 |
Bristol-Myers Squibb Company |
Aminopyrazole kinase inhibitors
|
EP2134875A2
(de)
|
2007-04-13 |
2009-12-23 |
Brystol-Myers Squibb Company |
Biomarker und verfahren zur bestimmung der empfindlichkeit gegen modulatoren des vaskulären endothelialwachstumsfaktors 2
|
US8198438B2
(en)
|
2007-04-18 |
2012-06-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
AU2008304620A1
(en)
*
|
2007-09-25 |
2009-04-02 |
Bayer Healthcare Llc |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
EP2215102B1
(de)
|
2007-10-01 |
2016-02-17 |
Ionis Pharmaceuticals, Inc. |
Antisense-modulation der expression des fibroblasten-wachstumsfaktor-rezeptors 4
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
NZ586642A
(en)
|
2008-01-11 |
2012-04-27 |
Natco Pharma Ltd |
Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
|
CA2716856C
(en)
|
2008-03-20 |
2013-02-19 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
US9126935B2
(en)
|
2008-08-14 |
2015-09-08 |
Amgen Inc. |
Aurora kinase modulators and methods of use
|
WO2010042684A1
(en)
*
|
2008-10-08 |
2010-04-15 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US8772481B2
(en)
|
2008-10-10 |
2014-07-08 |
Amgen Inc. |
Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
|
WO2010042649A2
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
|
US8101647B2
(en)
|
2008-10-17 |
2012-01-24 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole compounds and their use as therapeutic agents
|
CN102256983B
(zh)
|
2008-10-17 |
2017-04-05 |
泽农医药公司 |
螺羟吲哚化合物及其作为治疗剂的用途
|
US8710104B2
(en)
|
2008-11-07 |
2014-04-29 |
Triact Therapeutics, Inc. |
Catecholic butanes and use thereof for cancer therapy
|
WO2010071885A1
(en)
|
2008-12-19 |
2010-06-24 |
Cephalon, Inc. |
Pyrrolotriazines as alk and jak2 inhibitors
|
CA2748174A1
(en)
|
2008-12-30 |
2010-07-08 |
Arqule, Inc. |
Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(de)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
|
JP5656976B2
(ja)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
ピロロトリアジン化合物
|
AR077252A1
(es)
|
2009-06-29 |
2011-08-10 |
Xenon Pharmaceuticals Inc |
Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
|
CN105037355B
(zh)
|
2009-08-10 |
2017-06-06 |
萨穆梅德有限公司 |
Wnt信号传导途径的吲唑抑制剂及其治疗用途
|
CN102753556B
(zh)
|
2009-10-14 |
2015-05-13 |
泽农医药公司 |
螺-羟吲哚化合物的合成方法
|
US8088815B2
(en)
|
2009-12-02 |
2012-01-03 |
Hoffman-La Roche Inc. |
Spiroindolinone pyrrolidines
|
EP3001903B1
(de)
|
2009-12-21 |
2017-10-25 |
Samumed, LLC |
1h-pyrazolo[3,4-beta]pyridine und therapeutische verwendungen davon
|
US8288431B2
(en)
|
2010-02-17 |
2012-10-16 |
Hoffmann-La Roche Inc. |
Substituted spiroindolinones
|
BR112012021086A2
(pt)
|
2010-02-26 |
2016-05-17 |
Xenon Pharmaceuticals Inc |
composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
AU2011223655A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
JP2013522215A
(ja)
|
2010-03-09 |
2013-06-13 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
組合わせ抗癌療法
|
US8217044B2
(en)
|
2010-04-28 |
2012-07-10 |
Hoffmann-La Roche Inc. |
Spiroindolinone pyrrolidines
|
CA2799926A1
(en)
*
|
2010-05-28 |
2011-12-01 |
Biocryst Pharmaceuticals, Inc. |
Heterocyclic compounds as janus kinase inhibitors
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
US9464079B2
(en)
|
2011-03-23 |
2016-10-11 |
Semorex Technologies Ltd. |
Treatment of proliferative disorders with a chemiluminescent agent
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2721156B1
(de)
|
2011-06-16 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Antisense-modulierung der expression des fibroblastenwachstumsfaktor-rezeptors 4
|
KR20140036269A
(ko)
*
|
2011-07-01 |
2014-03-25 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
Alk1 억제제로서의 히드록시메틸아릴-치환된 피롤로트리아진
|
RU2627693C2
(ru)
|
2011-09-14 |
2017-08-10 |
СЭМЬЮМЕД, ЭлЭлСи |
ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/b-КАТЕНИНА
|
US9598416B2
(en)
|
2011-12-15 |
2017-03-21 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
|
UY34484A
(es)
|
2011-12-15 |
2013-07-31 |
Bayer Ip Gmbh |
Benzotienilo-pirrolotriazinas disustituidas y sus usos
|
WO2013124316A1
(en)
|
2012-02-23 |
2013-08-29 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN102675323B
(zh)
*
|
2012-06-01 |
2014-04-09 |
南京药石药物研发有限公司 |
吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
|
WO2014082230A1
(zh)
*
|
2012-11-28 |
2014-06-05 |
上海希迈医药科技有限公司 |
吡咯并三嗪类衍生物、其制备方法及其在医药上的应用
|
EP2943198B1
(de)
|
2013-01-08 |
2019-07-17 |
Samumed, LLC |
3-(benzoimidazol-2-yl)-indazolinhibitoren des wnt-signalwegs und therapeutische verwendungen davon
|
EP2948454B1
(de)
*
|
2013-01-24 |
2017-05-31 |
Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) |
Triazinverbindungen und verfahren zur herstellung davon
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
ES2616026T3
(es)
*
|
2013-03-11 |
2017-06-09 |
Bristol-Myers Squibb Company |
Pirrolopiridazinas como inhibidores de canales de iones potasio
|
ES2616025T3
(es)
*
|
2013-03-11 |
2017-06-09 |
Bristol-Myers Squibb Company |
Pirrolotriazinas como inhibidores de canales de iones potasio
|
US9499522B2
(en)
|
2013-03-15 |
2016-11-22 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US9334263B2
(en)
|
2013-10-17 |
2016-05-10 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
DK3057969T3
(en)
*
|
2013-10-17 |
2018-09-24 |
Blueprint Medicines Corp |
COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
|
WO2015081783A1
(zh)
*
|
2013-12-06 |
2015-06-11 |
江苏奥赛康药业股份有限公司 |
吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
|
CN104725381B
(zh)
*
|
2013-12-19 |
2018-04-10 |
南京圣和药业股份有限公司 |
生长因子受体抑制剂及其应用
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
WO2016022569A1
(en)
|
2014-08-04 |
2016-02-11 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016127068A1
(en)
|
2015-02-05 |
2016-08-11 |
Teva Pharmaceuticals International Gmbh |
Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
|
CN104876935B
(zh)
*
|
2015-05-18 |
2017-04-19 |
南方医科大学 |
2‑氨基吡咯并[1,2‑f][1,2,4]三嗪类化合物、合成方法及应用
|
AU2016297754A1
(en)
*
|
2015-07-24 |
2018-02-15 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to KIT and PDGFR
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2017024026A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10206908B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
CN108473491A
(zh)
|
2015-11-06 |
2018-08-31 |
萨穆梅德有限公司 |
2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途
|
BR112018072039B1
(pt)
*
|
2016-04-28 |
2023-12-26 |
Takeda Pharmaceutical Company Limited |
Composto, medicamento, e, uso do composto ou sal do mesmo
|
SG11201810683VA
(en)
|
2016-06-01 |
2018-12-28 |
Samumed Llc |
Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
|
EP3528808B1
(de)
|
2016-10-21 |
2021-10-06 |
BioSplice Therapeutics, Inc. |
Verfahren zur verwendung von indazol-3-carboxamiden und deren verwendung als hemmer des wnt/b-catenin-signalwegs
|
KR102558716B1
(ko)
|
2016-11-07 |
2023-07-21 |
사뮤메드, 엘엘씨 |
단일-투여량, 즉시-사용가능한 주사용 제제
|
KR102398659B1
(ko)
|
2017-03-17 |
2022-05-16 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 피롤로트리아진 유도체
|
US11040979B2
(en)
|
2017-03-31 |
2021-06-22 |
Blueprint Medicines Corporation |
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
|
US11459334B2
(en)
|
2018-04-16 |
2022-10-04 |
Shenzhen Targetrx, Inc. |
Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
|
MX2021012469A
(es)
|
2019-04-12 |
2022-01-18 |
Blueprint Medicines Corp |
Composiciones y metodos para el tratamiento de enfermedades mediadas por kit y pdgfra.
|
WO2021094209A1
(en)
|
2019-11-12 |
2021-05-20 |
Bayer Aktiengesellschaft |
Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
|